The curtains have risen on DCAT 2024 in the vibrant heart of New York City, and leading pharmaceutical companies from around the world have converged for a week of innovation, collaboration, and strategic dialogue.
In an encouraging development, neuromodulation, a form of bioelectric medicine, has emerged as a promising avenue for enhancing health by regulating the nervous system.
On Friday (March 15) leading pharma Auxilius Pharma announced promising results from the first-in-human clinical trial of its originative product-in-development, AUX-001.
In a significant move aimed at supporting patients battling amyotrophic lateral sclerosis (ALS), myTomorrows has announced a strategic partnership with the ALS Association, a leading nonprofit organization dedicated to combating ALS.
In the fast-evolving landscape of clinical trials, technological advancements play a vital role in streamlining processes, enhancing efficiency, and ultimately improving patient outcomes.
International pharmaceutical firm Angelini Pharma has initiated a creative crowdsourcing campaign aimed at enhancing target identification in epilepsy, particularly focusing on drug-resistant phenotypes.
A conversation between Colin Weller, VP and GM of the evidence platform at Medable and Liza Laws, senior editor, at Outsourcing Pharma, was held at this year’s SCOPE 2024 in Orlando.
On March 7, Celadon Pharmaceuticals plc, a leading UK-based pharmaceutical company specializing in cannabis-based medicines, unveiled promising findings from an early economic analysis of its chronic pain clinical trial, dubbed CANPAIN.
ClinOne, a leading provider of clinical trial technology, has unveiled what it calls a major enhancement to its platform, offering customers far more control and flexibility.
Clerkenwell Health, a company that delivers clinical trials for the treatment of complex mental health volunteers for trials into the use of psychoactive medications for treating PTSD, is in search of 40 ex-military volunteers.
Form Bio and Ginkgo Bioworkshave joined forces in what they call a groundbreaking partnership aimed at advancing AAV gene therapy design and development.
A Q&A session was held at SCOPE 2024 in Orlando, Outsourcing Pharma speaks with Kelly McKee, VP of decentralized clinical trials and patient registries, and Daniel Braga, VP of EHR and healthcare solutions.
By Progressive data analytics platform bioinformatics launched by Metabolon
Metabolon, Inc., a prominent figure in metabolomics solutions, has launched a seminal integrated bioinformatics platform, aiming to redefine metabolomics analysis in life sciences research.
Lifebit, a progressive biomedical data technology and services company, has reached a huge milestone, boasting a catalog of 100 million patients in its multi-omic and health data repository.
Yesterday, (February 28), a clinical-stage biotechnology company, Redx, announced that the first participant has been dosed in a phase 1 clinical trial for RXC008.
In a significant move to advance the landscape of digital pathology, Proscia has announced a partnership with Pramana, an AI-enabled health tech company.
Mandziuk is vice president, project management, eClinical Development & Delivery, at ICON’ and she says nothing could have prepared the health industry for the global impact the Covid pandemic has had.
Last week (February 22), it was announced a recent survey conducted jointly by Climedo and Siteworks has shed light on the perspectives of more than 65 primarily European-based study physicians.
Biogen Inc. has announced a significant advancement in the treatment of amyotrophic lateral sclerosis (ALS), commonly known as motor neuron disease (MND).
In a significant move aimed at revolutionizing Central Nervous System (CNS) research, eCOA/ePRO platform provider uMotif has announced a strategic partnership with MoCA Cognition, the creators of a recognized test for early cognitive impairment detection.
Results from a phase 3 trial looking at treatment for primary biliary cholangitis (PBC) are 'genuinely exciting' and support the potential for seladelpar to raise the bar in treatment of the disease.
In the fast-evolving landscape of healthcare and pharmaceuticals, the role of technology, particularly artificial intelligence (AI), is becoming increasingly prominent.
The National Institute for Health and Care Excellence (NICE) has issued guidance recommending GSK's Omjjara (momelotinib) as a treatment option for disease-related splenomegaly.
An international initiative that recognizes, rewards, and benchmarks the reputations of pharma companies in patient engagement and centricity has opened.
Creating artificial intelligence to understand medical conditions, and not just the English language, sounds far-fetched, but this is what one CEO is achieving with an impressive foundational innovation.
Jane Kendrew changed paths after a year of her first degree knowing it was exactly the right way for her. She left university with a first class honours degree and turned down the offer of a PhD to start her dream job as a research scientist.
A clinical-stage biotechnology company creating a new class of drugs today (Feb 20) announced that a first subject has been dosed in a phase 1 clinical trial.
The father of a boy diagnosed with acute lymphoblastic leukemia at the age of nine, inspired by his son's love of collecting, has created patches of positivity for children going through cancer treatment to collect.
At most major conferences, there is usually a topic or buzzword that everyone talks about - and at this year’s SCOPE held in Orlando this week, it was no different.
Biogen Inc. has taken a step closer to bringing its ‘groundbreaking treatment’ to patients with a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder.
With independent pharmacies now facing significant challenges, healthcare SaaS provider Charac was pleased to announce more investment so it can accelerate a digitization drive.
Phesi’s artificial intelligence (AI) driven platform, Trial Accelerator, has reached a milestone and now contains global data from more than 100 million patients.
An artificial intelligence (AI)-powered tool from UK-based Brainomix was one of only two products to be endorsed by health assessor the National Institute of Health and Care Excellence (NICE).
Results from a new research project have been announced by technology provider Medable on the enhanced electronic informed consent (elC) in clinical trials.
No new treatments to combat the major public health issue of alcohol use disorder (AUD), have been brought to market for ten years - and with half of heavy drinkers refusing the abstinence route, new drug could be the answer.
A company building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (pathway) has announced a further extension to its series B financing round.
A husband-and-wife team keen to find a solution to an ‘NHS in crisis’ have secured $1.5 million in seed funding for their UK-based startup providing AI-powered clinical and drug prescription services for minor conditions.
GSK plc’s small molecule Omjjara (momelotinib), was granted marketing authorization (MA) yesterday (January 31) by the Medicines and Healthcare products Regulatory Agency (MHRA).
With colorectal cancer (MRC) being the second biggest cancer type in Hong Kong, it is positive news that Hutchmed has received marketing approval for its Elunate (fruquintinib) small molecule treatment.